At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 50 enrolled
Drug / intervention
Endostatindrug
Likely dose
Endostatin 7.5mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Clinical Trial of Recombinant Human Endostatin in Combination With Concurrent Chemo-Radiotherapy in the Patients With Unresectable Stage III Non-small-Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Endostatin for Non-small Cell Lung Cancer. Targeting 50 participants across 1 site.
Detailed Summary
To evaluate the efficacy and safety of Endostar combined with concurrent chemo-radiotherapy (CCRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
CollaboratorsAffiliated Hospital of Guangdong Medical University, Fujian Province Tumor Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University, The Affiliated Tumor Hospital of Guangxi Medical University, Zhejiang Cancer Hospital, Guangzhou General Hospital of Guangzhou Military Command, The 458 Hospital of Chinese PLA
Timeline
Phase 2UnknownOverdue
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
First PostedOct 2010
Primary CompletionDec 2013
Study CompletionDec 2015
TodayJul 2026
First PostedOct 11, 2010
Enrollment StartMay 1, 2009
Primary CompletionDec 1, 2013
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 15.7 years ago
Interventions
Endostatindrug
7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks